Ontology highlight
ABSTRACT: Background
Single agent immune checkpoint inhibitors (ICIs) improve survival outcomes compared to chemotherapy for advanced non-small cell lung cancer (NSCLC), but treatment efficacy widely varies. The combination of ICIs with chemotherapy has shown promising efficacy over chemotherapy alone; however, whether this strategy is superior to single agent ICIs for the treatment of advanced NSCLC remains unknown.Methods
The records of 109 patients with advanced NSCLC who were administered at least one cycle of ICIs were retrospectively reviewed. Patients were grouped based on the presence or absence of a chemotherapy treatment combination. Efficacy and survival outcomes were analyzed.Result
Sixty-nine (58.0%) patients received single agent ICIs (ICI group) and 50 (42.0%)
SUBMITTER: Kuo CS
PROVIDER: S-EPMC6501017 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature